Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients

Bone Marrow Transplantation

Volumn 18, Issue 3, 1996, Pages 565-568

  Ljungman, P ^a,c   Oberg G ^b   Aschan, J ^a   Ehrnst, A ^c   Lonnqvist B ^a   Pauksen, K ^b   Sulila, P ^d  

^a Department of Hematology   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Astra Arcus AB   (Sweden)

Author keywords

CMV; Foscarnet; PCR; Pre emptive therapy

Indexed keywords

CALCIUM; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FOSCARNET; GANCICLOVIR; MAGNESIUM; METHOTREXATE; POTASSIUM; THYMOCYTE ANTIBODY;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; ELECTROLYTE BLOOD LEVEL; GRAFT VERSUS HOST REACTION; HEADACHE; HEMORRHAGIC CYSTITIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAGNESIUM BLOOD LEVEL; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SCHOOL CHILD; URETHRITIS; VIRUS ISOLATION;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; BONE MARROW TRANSPLANTATION; CHILD; CYTOMEGALOVIRUS INFECTIONS; FOSCARNET; HUMANS; MIDDLE AGED; PILOT PROJECTS; POLYMERASE CHAIN REACTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 0029792611     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Ehrnst A, Barkholt L, Brattström C et al. Detection of CMV-matrix pp65 antigen in leucocytes by immunofluorescence as a marker of CMV disease. J Med Virol 1993; 39: 118-124.
2. Ehrnst A, Barkholt L, Levensohhn-Fuchs I et al. CMV PCR monitoring in leukocytes of transplant patients. Clin Diagn Virol 1995; 3: 139-153.
3. Boeckh M, Bowden RA, Goodrich JM et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992; 80: 1358-1364.
4. Ljungman P, Loré K, Aschan J et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive therapy in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1996; 17: 583-587.
5. Einsele H, Ehninger G, Hebart H et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side-effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-2820.
6. Klintmalm O, Lönnqvist B, Öberg B et al. Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. Scand J Infect Dis 1985; 17: 157-163.
7. Reusser P, Gambertoglio J, Lilleby K et al. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis 1992; 166: 473-479.
8. Bacigalupo A, Tedone E, Van Lint MT et al. CMV prophylaxis for foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant 1994; 13: 783-788.
9. Ringdén O, Ruutu T, Remberger M et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-2730.
10. Porter-Jordan K, Rosenberg E, Keiser J et al. Nested polymerase chain reaction assay for the detection of cytomegalovirus overcomes false positives caused by contamination with fragmented DNA. J Med Virol 1990; 30: 85-91.
11. Ljungman P, Griffiths P. Definitions of cytomegalovirus infection and disease. In: Michelson S, Plotkin SA (eds). Multidisciplinary Approach to Understanding Cytomegalovirus Disease. Excerpta Medica International Congress Series: Amsterdam, 1993, pp 223-240.
12. Goodrich JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. New Engl J Med 1991; 325: 1601-1607.
13. Vlieger A, Boland G, Jiwa N et al. Cytomegalovirus antigenemia assay or PCR can be used to monitor ganciclovir treatment in bone marrow transplant recipients. Bone Marrow Tramplant 1992; 9: 247-253.
14. Ringdén O, Wilczek H, Lönnqvist B et al. Foscarnet for cytomegalovirus infections. Lancet 1985; i: 1503-1504 (letter).